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The modern approach for metastatic colorectal cancer (mCRC) patients is
based on the identification of oncogenic pathways, which could be targeted
by specific molecules. Vascular endothelial growth factor (VEGF)- and epithe-
lial growth factor receptor (EGFR)-related pathways represent the most
important biological mechanisms for cancer development and progression.
However, the most significant results by VEGF and EGFR targeting could be
achieved through the combination of these drugs with standard chemothera-
peutic regimens. These strategies aim to improve the resectability of liver and
lung metastases. For those patients who cannot be eligible for metastases
resection, a ‘continuum of care’ has been proposed as the best option. This
strategy includes the sequential delivery of various regimens with different
targeted drugs. For this reason the choice of the pathway to target, that is,
VEGF or EGFR, is not a real dilemma since both these molecules would be tar-
geted during the mCRC natural history. To date, a selection by KRAS muta-
tional status is mandatory to identify those patients with higher probability
of benefit from anti-EGFR monoclonal antibodies. In this case VEGF targeting
is the only way to choose. Newmolecules are under evaluation to widen these
treatment options.
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Long time has passed since the role of various molecular pathways was stated for
colorectal cancer (CRC) pathogenesis. Genetic and epigenetic alterations were
located in the different steps of colorectal carcinogenesis, as Vogelstein proposed
in 1990 [1]. Some genetic mutations seem to prompt a predominant role of partic-
ular oncogenes for cancer development and progression, as defined by the ‘oncogene
addiction’ model. On these bases new drugs were developed to target specific molec-
ular pathways. To date, vascular endothelial growth factor (VEGF)-mediated angio-
genetic mechanisms and epithelial growth factor receptor (EGFR)-related
proliferation are the best studied biological processes in CRC. The former repre-
sents a way for the connection between cancer cells and the host, through the stroma
in tumor microenvironment. The latter is the main regulator of homeostasis in the
intestinal epithelium, but in cancer cells it could turn to constitutive activation by
genetic mutations in those genes implicated in its signaling transduction pathway.
Three monoclonal antibodies (moAbs) were developed and approved for clinical
use to target these phenomena of cancer cell function. Bevacizumab is directed
against soluble VEGF-A, and Cetuximab and Panitumumab bind EGFR to block
its signaling transduction [2,3].
These moAbs showed limited antitumor activity as single agents in some clinical
trials [4,5]. However, an improvement of both tumor response and survival
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endpoints was obtained when combined with backbone che-
motherapeutic regimens, including fluoropyrimidines alone
or with oxaliplatin or irinotecan [6-9]. A 25-month median
overall survival has been overcome since these moAbs were
introduced in the treatment strategies for metastatic CRC.
The first-line treatment has always been considered the
main setting to evaluate the real efficacy of a particular thera-
peutic regimen. However, recently the sequential application
of different chemotherapy regimens is becoming the main
goal for those patients for whom cure could not be achieved.
For this reason this approach is usually described as
‘continuum of care.’ By this perspective the choice of a che-
motherapy regimen and a targeted drug to combine with it
is not a fundamental matter, since the real aim is to have
many different treatments to control metastatic CRC and
related symptoms as long as possible.
A recent trial showed the feasibility of continuation of
bevacizumab after first-line progression changing the associ-
ated chemotherapeutic regimen [10]. New anti-angiogenetic
drugs such as aflibercept, a VEGF inhibitor, induced further
benefit after first-line treatment with bevacizumab-based
regimens [11]. These findings suggest a predominant role of
angiogenesis in CRC progression and the possibility to pro-
long survival benefit in mCRC patients through sequential
inhibition of the angiogenetic pathway in the various lines
of treatment, above all for those patients with KRAS mutated
tumors. We propose that these different strategies could offer
more options according to the tumor aggressiveness (i.e., afli-
bercept for symptomatic patients with earlier progression
after first-line bevacizumab; bevacizumab beyond progression
for those patients experiencing later progression or with
asymptomatic disease).
The choice for a particular targeted drug for combination with
chemotherapy, as first-line challenge, becomes relevant just for
those patients who need intensive therapy for potentially resect-
able metastases, tumor-related symptoms, high tumor volume,
or high rate of progression [12]. For these cases the anti-EGFR
moAbs seem to achieve higher response rates and resection rates
than anti-VEGF moAbs when combined with first-line chemo-
therapy. Anyway these results are more evident in selected than
unselected patients, in particular for KRAS mutational status
and metastatic number and sites [13]. Even if a selection could
be made for patients with a higher probability of efficacy deriving
from anti-EGFRmoAbs, no studies founded biomarkers for pre-
diction of efficacy induced by bevacizumab [14]. Recently a role as
predictive factor of anti-angiogenetic therapy has been recognized
to sVEGFR-2 [15]. New methods of selection have been also
tested for anti-EGFR moAbs, since KRAS mutations were
detected in circulating DNA, yielding an easier way of detection
for clinical practice [16,17].
To date, we lack evidence for difference of efficacy between
anti-VEGF and anti-EGFR moAbs. All considerations we
could report are obtained by extrapolation from various spe-
cific clinical trials. Some authors supposed the potential syner-
gism between angiogenesis and EGFR-related pathway.
Clinical trials were designed to test the feasibility of a regimen
including both chemotherapy, bevacizumab and panitumu-
mab or cetuximab. These triple combinations appeared to
be detrimental in mCRC patients [18,19].
Recently, a new interesting philosophical approach has
been emerged in the clinical practice scenario: the potential
role of anti-EGFR-based therapy rechallenge during the
‘continuum of care’ of mCRC patients [20]. This clinical
choice is based on the hypothesis that the progression after
an initial treatment response in wild-type KRAS primary
tumors could be due to the selection of a mutated clone,
rather than to a late acquisition of a KRAS mutation, based
on a sort of ‘anti-EGFR-driven mutated genotype acquisition’
during therapy. This new approach, if will be confirmed, may
further delay the disease progression and improve therapeutic
options for mCRC patients.
Even toxicity profile is quite different between these two
kinds of targeted agents. Anti-EGFR moAbs are able to
induce skin toxicity mainly, since EGFR-targeting is not
specific for cancer cells and could affect also cutaneous epithe-
lium. VEGF inhibition can prompt hypertension, proteinuria
and hemorrhage or thrombosis. In few cases the adverse
effects from both anti-EGFR and anti-VEGF drugs imposed
a treatment withdrawal. Rarely these effects were serious or
life-threatening. For this reason the differential toxicity profile
is not a valid criterion to choose the proper biological drug in
mCRC patients.
In conclusion we could propose that the choice of VEGF-
or EGFR-targeting agents in mCRC patients does not repre-
sent a real dilemma. In fact each combination of a targeted
drug with chemotherapy could find a proper location in the
overall treatment strategy as a ‘continuum of care,’ above all
if we consider tumor and patient characteristics. For example,
mutant KRAS-bearing tumors keep from anti-EGFR moAbs
use. So the patients with mutated KRAS can benefit just
from the addition of bevacizumab to chemotherapy.
Another particular situation is represented by those mCRC
patients with potentially resectable metastases and wild-type
KRAS, because anti-EGFR moAbs combined with chemo-
therapy could achieve higher tumor response rates and subse-
quently higher probability of respectability. Until a clear
evidence is not available through direct comparison between
anti-VEGF and anti-EGFR moAbs, the choice for a particular
drug in first-line treatment could be based only on physician’s
experience and deductive considerations from completed
clinical trials.
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